{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-031974","form_type":"8-K/A","ticker":"NMRA","cik":"0001885522","company_name":"Neumora Therapeutics, Inc.","filed_at":"2025-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.480034+00:00","generated_at":"2026-05-26T07:15:16.470022+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Neumora Therapeutics appoints Paul Berns as Chairman & CEO, Gosebruch exits","bullets":["Henry Gosebruch separates as CEO; receives 12-month base salary, 2025 target bonus, 18-month COBRA, 2024 bonus, and 12-month option exercise period.","Paul L. Berns appointed Chairman & CEO with $700,000 base salary and 60% annual bonus target, effective Feb 14, 2025.","Berns receives option to purchase 2,000,000 shares vesting over 4 years (25% after 1 year, monthly thereafter).","Berns severance: 12 months salary + bonus (non-CIC); 24 months salary + 2x bonus + equity acceleration (CIC-related)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-031974","json":"https://secwatch.observer/filing/0001193125-25-031974.json","markdown":"https://secwatch.observer/filing/0001193125-25-031974.md","text":"https://secwatch.observer/filing/0001193125-25-031974.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525031974/0001193125-25-031974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525031974/d862857d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T07:15:16.470022+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"36bcff4dfd","claim":"Henry Gosebruch departed as President and Chief Executive Officer at Neumora Therapeutics, Inc..","evidence_excerpt":"the Company has entered into a Separation Agreement, dated February 14, 2025, with Henry Gosebruch, the Company’s former President and Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525031974/0001193125-25-031974-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"separated"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"9643877801","claim":"Paul L. Berns was appointed as Chairman and Chief Executive Officer at Neumora Therapeutics, Inc..","evidence_excerpt":"an Executive Employment Agreement, effective as of February 14, 2025, with Paul L. Berns, as the Company’s Chairman and Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312525031974/0001193125-25-031974-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairman and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}